Delhi HC Upholds FSSAI Ban on Misleading ‘ORS’ Labels, Citing Public Health

In a significant ruling prioritizing public health over commercial interests, the Delhi High Court has refused to interfere with a directive from the Food Safety and Standards Authority of India (FSSAI) that prohibits beverage companies from using the term 'ORS' on products that do not conform to the World Health Organization's (WHO) medical formulation.

The decision, delivered by Justice Sachin Datta, dismisses the challenge brought by Dr. Reddy's Laboratories Ltd., which sought to continue selling its existing stock of 'Rebalanz VITORS', an oral rehydration solution brand. The court underscored the potential public health hazard posed by products misleadingly branded as ORS, a term synonymous with a specific, life-saving medical formula for dehydration.

"Public health considerations are paramount. We can't pass any orders against it," the court stated unequivocally, reinforcing the regulator's authority in matters of public safety. This ruling serves as a critical precedent for the food and pharmaceutical industries, affirming that trademark rights and commercial considerations cannot override statutory regulations designed to prevent consumer deception and health risks.

---

The Core of the Dispute: Misleading Labels and Public Health

The legal battle stems from FSSAI's order issued on October 14, which withdrew all prior permissions for food and beverage companies to use the 'ORS' (Oral Rehydration Solution) acronym in their product branding unless the product strictly adheres to the WHO-prescribed formulation. The regulator argued that many commercial electrolyte and sugary drinks were leveraging the 'ORS' branding, creating a dangerous confusion for consumers.

Genuine ORS is a scientifically balanced composition of glucose and electrolytes recommended by the WHO for treating dehydration, especially in vulnerable populations like children suffering from diarrhea. The FSSAI contended that commercial beverages using the term, which often contain high sugar levels and different nutritional profiles, violate the Food Safety and Standards Act, 2006 by misleading the public.

Dr. Reddy's Laboratories approached the High Court challenging this directive, specifically concerning its product 'Rebalanz VITORS'. The company informed the court that it had already ceased manufacturing new batches of the product and was prepared to re-sticker existing stock in its possession. However, it sought interim relief to sell off the stock already distributed in the market, a request the court firmly denied.

Justice Datta’s Firm Stance on Non-Interference

In a decisive observation, Justice Sachin Datta emphasized the gravity of the issue, framing it as a non-negotiable matter of public welfare. "It is a health hazard... This embargo will continue. I am not disturbing this embargo given the public health considerations," the judge declared.

The court refused to grant any interim relief that would permit the continued sale of the existing, non-compliant products. Instead, it provided a practical, albeit commercially challenging, path forward for the company. Justice Datta suggested that Dr. Reddy's could re-sticker its existing products, a solution to which FSSAI had no objection. The company's counsel affirmed their willingness to do so for stock within their control and even attempt to recall and re-sticker products from stockists.

Recognizing the logistical difficulties, the court granted the company liberty to make a formal representation to the FSSAI to explore a "via media" for managing the existing stock. However, it was made clear that any such arrangement must not compromise public health. "I am not enforcing any via media which will compromise public health consideration, that is for FSSAI to consider," Justice Datta added, indicating that the court would set timelines for the regulator to decide on Dr. Reddy's plea.

Broader Industry Impact and a Long-Fought Campaign

The FSSAI's directive and the High Court's subsequent endorsement affect a wide range of pharmaceutical and food companies that have built significant market presence with ORS-branded electrolyte drinks. One of the most prominent brands, ORSL, manufactured by JNTL Consumer Health India, reportedly had an inventory worth approximately ₹180 crore when the ban was announced.

This regulatory action is the culmination of an eight-year advocacy campaign led by Dr. Sivaranjani Santosh, a Hyderabad-based paediatrician. Dr. Santosh consistently argued that commercial products like ORSL were dangerously marketed with medical-sounding names despite deviating significantly from the WHO's life-saving formula. Her campaign highlighted the risk of consumers using these high-sugar beverages for medical purposes, potentially worsening conditions like dehydration.

The court's proceedings also brought to light a previous instance of misinterpretation. An earlier consent order on October 17, involving JNTL, was widely misconstrued on social media as a judicial green light for companies to continue selling ORS-labeled drinks. Justice Datta had to issue a strong clarification on October 28, stating that the order was merely to enable FSSAI to pass a reasoned decision and was never intended to permit the continued manufacturing of such products.

Legal Implications and the Road Ahead

This judgment reinforces a crucial principle of administrative and regulatory law: judicial deference to expert bodies on matters of public health and safety. The court's refusal to substitute its judgment for that of the FSSAI demonstrates a respect for the regulator's domain expertise and statutory mandate under the Food Safety and Standards Act, 2006.

For legal practitioners in food, drug, and intellectual property law, the case highlights the tension between trademark rights and public interest regulations. While a brand may have a registered trademark containing terms like 'ORS' (often with prefixes or suffixes), this right is not absolute and can be restricted by statutory authorities to prevent consumer harm.

The key takeaways for the industry are:

1. Compliance is Non-Negotiable: Regulatory standards, especially those concerning health, will be strictly enforced. The court has signaled that it will not entertain arguments for commercial leniency when public safety is at stake.

2. Proactive Rebranding is Essential: Companies affected by the ban must now focus on rebranding their products and educating consumers about the change, a significant marketing and logistical challenge.

3. Future Product Development: Any new product development in the health and wellness beverage sector must carefully consider labeling and branding to avoid misleading claims or using medically significant terminology inappropriately.

As the FSSAI prepares to consider the representation from Dr. Reddy's Laboratories, the industry will be watching closely. The outcome will set a precedent for how regulators and companies navigate the disposal of non-compliant inventory, balancing commercial losses with the unyielding imperative of public health protection.